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Abstract
Background: BRAF mutations are present in 40 % of human skin melanomas. Mutated tumors with an increased
percentage of BRAF mutant alleles (BRAF-M%) may have a better response to RAF/MEK inhibitors. We evaluated the
BRAF-M% in melanomas, and the genetic causes of its variation.
Methods: BRAF-M% was quantified by pyrosequencing, real-time PCR (rtPCR) and/or picoliter-droplet PCR (dPCR).
BRAF mutant expression was detected by immunohistochemistry. Chromosomal alterations were analyzed with
fluorescence in situ hybridization (FISH), and single nucleotide polymorphism (SNP) arrays.
Results: BRAF-M% quantification obtained with pyrosequencing was highly correlated (R = 0.94) with rtPCR, and with
dPCR. BRAF-M% quantified from DNA and RNA were also highly correlated (R = 0.98). Among 368 samples with >80 %
tumor cells, 38.6 % had a BRAFV600E mutation. Only 66.2 % cases were heterozygous (BRAF-M% 30 to 60 %). Increased
BRAF-M% (>60 %) was observed in 19 % of cases. FISH showed a polysomy of chromosome 7 in 13.6 %, 35.3 %
and 54.5 % of BRAF wild-type, heterozygous and non-heterozygous BRAF-mutated samples, respectively (P < 0.005).
Amplification (5.6 %) and loss (3.2 %) of BRAF locus were rare. By contrast, chromosome 7 was disomic in 27/27
BRAF-mutated nevi.
Conclusions: BRAF-M% is heterogeneous and frequently increased in BRAF-mutant melanomas. Aneuploidy of
chromosome 7 is more frequent in BRAF mutant melanomas, specifically in those with high BRAF-M%.
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Background
Since the discovery of gain of function mutations in the
proto-oncogenes NRAS [1] and BRAF [2], thousands of
human skin melanoma samples have been analyzed, and
the estimated incidence of NRAS and BRAF mutations
are 18 % and 41 %, respectively [3]. These mutations are
often mutually exclusive [4, 5]. The BRAF locus is local-
ized on chromosome 7q, and most BRAF mutations in-
volve the kinase activation loop at the p.V600 position.
The most common BRAF mutation is a substitution of a
valine to a glutamic acid (c.1799 T > A, p.V600E). BRAF
V600E accounts for 85 % of exon 15 mutations in the
most recent studies [6, 7]. Another mutation, V600K is
present in 9 % of melanomas. These BRAF mutations
constitutively activate the MAPK signaling pathway [8].
Two BRAF inhibitors, vemurafenib and dabrafenib, tar-
geting the BRAF p.V600 mutated protein, have recently
been shown to prolong the progression-free and/or the
overall survival of BRAF V600-mutated advanced melan-
oma, as compared to dacarbazine [9–11]. However, both
are limited by the development of acquired resistance in
many patients, with a median progression-free survival
(PFS) of 6.9 and 6.7 months for vemurafenib and dabrafe-
nib, respectively [10, 12].
Mechanisms underlying acquired resistance to BRAF in-
hibitors have been extensively studied, and most of them
involve acquired mutations within the same RAS-RAF-
ERK pathway [13]. By contrast, only little data is available
concerning biomarkers of good/prolonged response to
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BRAF inhibitors. Recently, a high ratio of mutant/wild-
type alleles of BRAF was reported to be associated with a
good response to BRAF inhibitors [14].
Like most oncogenes, somatic mutations of BRAF are
thought to be heterozygous in tumors. Some studies re-
ported that BRAF mutations are not heterozygous in
some cases [15]. Additionally, in contrast to wild-type
BRAF, which is only active as a dimer, products of alleles
with gain of function mutations are also active as mono-
mers [16].
We present herein a validated quantification of mu-
tated BRAF in a large series of human skin melanoma
samples, and demonstrate that several cases are not het-
erozygous. We also present the results of a genetic study
on mechanisms of the BRAF mutant allele increase in
melanoma.
Methods
Samples and nucleic acid extraction
All samples were obtained from the bank of biological
resources of Ambroise Paré Hospital. All surgical or fine
needle biopsies were performed for routine diagnosis or
evaluation of disease progression. The research was per-
formed in compliance with the ethical principles of the
Helsinki Declaration (1964). In accordance with French
ethics laws, all patients were informed that part of their
samples could also be used for research purposes, and
that they could refuse this. None of patients refused the
use of samples for research. Tumor sample collection
was declared to the French Ministry of Research (DC
2009-933) and CPP IDF 8 ethics committee approved
the MelanCohort study (030209), which is registered
with Clinicaltrials.gov (NCT00839410). Signed informed
consent for translational research was obtained from pa-
tients still alive. All diagnoses were confirmed by path-
ology review.
For most of the nucleic acid quantification studies, the
tumor DNA was extracted from formalin fixed paraffin
embedded (FFPE) tissue. However, for mRNA extraction
and high density SNP analysis, frozen samples were used.
In all cases, a 4 micrometers-thick section was stained
with hematoxylin & eosin and reviewed by a pathologist
before extraction, to confirm the presence of melanoma
and to select areas with the highest density of tumor cells
for macrodissection. For all samples, tumors cell content
was estimated in the percentage of tumor cells and the
data was noted. To evaluate the accuracy of tumor cell
content assessment, a series of 41 randomly selected sam-
ples was assessed by three independent pathologists.
For each sample, serial sections or punch sampling were
then used for nucleic acid extraction. For DNA extraction,
samples were digested by an overnight incubation in the
presence of proteinase K, followed by the application of the
QIAamp DNA mini kit (Qiagen, Courtaboeuf, France) as
previously described [17]. The RNeasy Mini Kit (Qiagen)
was applied for RNA extraction. DNA and RNA were con-
trolled with a spectrophotometer (ND-100, Nanodrop®).
Real-time PCR
Real-time PCR (rtPCR) was performed as previously de-
scribed [18]. 1 μL of DNA brought to 25 ng/μL was ap-
plied to each reaction mixture. The amplification reaction
was performed in Applied Prism 7900 HT (Thermo Fisher
Scientific, Illkirch, France). Each sample was analyzed in
two different reaction mixes: in the first one, all BRAF al-
leles present in the tumors were amplified; in the second
one, only the mutated allele was detected by peptide nu-
cleic acids (PNAs)-specific inhibition of wild-type (WT)
allele amplification. Each PCR reaction was carried out in
duplicate. The primers and probe sequences were pub-
lished previously [17]. The relative quantification method
was used to compare expression levels of wild type allele
and BRAF V600E mutated allele using comparative Ct
method as described by Livak et al. [19].
Picoliter-droplet digital PCR
Picoliter-droplet digital PCR (dPCR) testing was performed
using previously described protocols [20, 21] with the Rain-
drop Instrument (RainDance Technologies, Billerica, MA).
Shortly, in a pre-PCR environment, 12.5 μL Taqman Geno-
typing Master Mix (Life Technologies, Saint Aubin, France)
was mixed with the assay solution. The assay solution con-
tained: 0.75 μL of 40 mM dNTP Mix (New England Bio-
Labs, Evry, France), 0.5 μL of 25 mM MgCl2, 2.5 μL of 10x
Droplet Stabilizer (RainDance Technologies), 1.25 μL of
20x Taqman® Assay Mix containing 8 μM of forward and
reverse primers, 200 nM of 6-FAM and 200 nM of VIC
Taqman® labelled-probes (Additional file 1) and target
DNA template to a final reaction volume of 25 μL. A mini-
mum of 280 ng of DNA was used in each assay. 5 millions
highly monodispersed droplets were generated using the
Raindrop source instrument following manufacturer’s in-
structions. The emulsions were submitted to thermocy-
cling, starting with 2 min at 50 °C, 10 min at 95 °C,
followed by 45 cycles of: 95 °C, 15 s and 60 °C, 1 min (using
a 0.6 °C/min ramp rate). After completion, the end-point
fluorescence signals from each droplet were measured
using the Raindrop Sense instrument. Analyses of the data
were performed using the Raindrop analyst software as pre-
viously described [20, 21]. The reference sequence was B-
RAF cDNA sequence (GenBank NM_00433.4).
Pyrosequencing
Pyrosequencing was performed as previously described
[22]. It is a method of DNA sequencing based on the "se-
quencing by synthesis" principle. The results are displayed
in the form of peaks corresponding to the detection of
pyrophosphate release after nucleotides incorporation
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(pyrogram). Peak area is proportional to the number of in-
dividual nucleotide incorporated to the sequence; thus
allowing the relative quantifications of mutated and WT
alleles. RNA was transcribed to cDNA and FFPE tumor
DNA concentrations were brought to 10 and 20-25 ng/μL
prior to PCR amplification. Primers used for FFPE tumor
DNA amplification and pyrosequencing were published
previously [17]. Biotinylated amplicon was verified on
agarose gel and analyzed with PyroMark 24 (Qiagen) ac-
cording to manufacturer recommendations. Primers used
for frozen tumor DNA/RNA amplification and pyrose-
quencing are presented in Additional file 1.
FISH and Immunohistochemistry
Tissue microarray (TMA) was performed for 141 sam-
ples of melanomas (140 patients) and 42 samples of mel-
anocytic nevi (junctional, intradermal and compound) of
more than 4 mm long axis. For each tumor, three cores
of 0.6 mm diameter from distinct tumor regions were
spotted onto the slides.
For immunohistochemistry, the VE1 antibody was used
as previously described [17, 23]. Detection of BRAF
p.V600E mutated protein with VE1 has been shown to have
a high sensitivity, specificity and reproducibility. Intensity of
staining was evaluated by two independent observers on a
semi-quantitative scale of 0–3. The VE1 antibody was
scored as negative (0) when there was no staining, weak
staining of single interspersed cells, or staining of mono-
cytes/macrophages. Positive staining was scored as: weakly
positive staining (1), moderately positive staining (2) and
strongly positive staining (3) of melanoma cells. Cases were
considered not interpretable when nuclear staining was
present. Cases were scored as ambiguous if immunostain-
ing could not be scored as positive or negative.
For FISH analysis, TMA section slides of 4 micrometers
were stored at -20 °C and hybridization was performed
within 2 weeks of cutting. All samples were analyzed with
the RP11-121G9 BAC probe covering the BRAF gene. The
chromosome 7 centromere probe was used as reference
probe (Agilent Technologies, Les Ulis, France). A total of
53 tumor samples were also analyzed with the commer-
cially available BRAF probe, SureFISH 7q34 BRAF (Agi-
lent Technologies), together with the chromosome 7
centromere probe. For home-made probes, bacteria carry-
ing a BAC vector were grown overnight onto solid agar
medium, followed by an overnight proliferation in a LB
medium. BAC DNA was extracted using NucleoBond PC
500 or NucleoBand Xtra BAC Kits (Macherey-Nagel,
Hoerdt, France) as recommended by supplier. 1 μg of
DNA was labeled by nick-translation reaction according
to manufacturer’s instructions (Abbott Molecular Inc.,
Rungis, France). After overnight precipitation at -20 °C in
the presence of human cot DNA, sodium acetate and
ethanol, the probe was resuspended in the hybridization
buffer (LSI/WCP Hybridization Buffer)(Abbott Molecular
Inc). They were used at a final concentration of 40-50 ng/
μL. FFPE slides were prepared for hybridization using
Histology FISH accessory KIT (DAKO, Les Ulis, France).
Commercial probes were applied according to the manu-
facturer’s recommendations (Agilent Technologies) and a
co-denaturation of the probes and the tumor section were
performed to create single-stranded DNA. The probes
and the slides were denaturated separately when BRAF
BAC probes were used together with commercial chromo-
some 7 centromere probe. Before an overnight incubation
in a humidified chamber, a suppression of the repetitive
sequences was performed for DNA BRAF BAC (45 min at
37 °C). After post-hybridization wash, and DAPI staining
in the Vectashield® Mounting Media (Vector Laboratories,
Les Ulis, France), fluorescence signals were analyzed using
a Leica DM4000B microscope equipped with appropriate
filters and a DFC300FX camera under the control of LAS
V4.0 software (Leica). Two independent analyses were
performed.
SNP analysis
DNA was extracted from frozen melanoma samples and
hybridized on HumanCore BeadChip (Infinium Ilumina®,
Evry, France) according to the manufacturer’s instructions
by IntegraGen. This array contains more than 240,000
highly-informative genome-wide tag SNP and over 20,000
high-value markers. Chromosome 13p, 14p, 15p, 21p
and 22p markers are not represented in this array.
Chromosome Y and X were only used to control the
gender of the patient. All genome positions were based
upon NCBIGRCh37/hg19 from UCSC Genome Bio-
informatics. The genotyping data were normalized by
the IntegraGen commercial platform and analyzed
(copy number aberrations (CNA) and allele disequilib-
rium (AD)) using GenomeStudio software (version 1)
(Illumina Inc).
The Cancer Genome Atlas Dataset
For external validation of our results on an independent
cohort, the skin melanoma dataset of The Cancer Gen-
ome Atlas (TCGA)(Provisional) was downloaded through
the cBioPortal for Cancer Genomics website (http://
www.cbioportal.org/ date March 13th 2015). We selected
“All Complete Tumors (278)” of the patient/case set and
entered the BRAF gene in the TCGA (Provisional) dataset.
The cBioPortal website provided the data about mutation
type, amino acid change and variant allele frequency. Ana-
lysis was performed as published [24].
Statistic analyses
The correlations between the percentage of mutated BRAF
in cDNA/gDNA and in rtPCR/pyrosequencing analysis
were tested by estimating the coefficient of correlation.
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The chi2 test supplemented when necessary in Yates
correction was used to analyze the differences between dif-
ferent BRAF-M% groups and chromosome 7 status. The t-
test was used to compare tumors with less or more than
80 % of tumor cells. The results were considered significant
when P < 0.05.
Results
Validation of BRAF mutated allele quantification
The percentage of BRAF mutant alleles (BRAF-M%) in pa-
tients with melanoma was evaluated with two quantitative
methods. Both pyrosequencing and real-time PCR allowed
quantification of the relative amount of c.1799 T >A sub-
stitution. However these methods are only used qualita-
tively in determining BRAF status in clinical practice. We
analyzed DNA extracted from 77 FFPE melanoma samples
with both methods, and found a high positive correlation
(R = 0.94) of BRAF-M% (Additional file 2A). For 7 samples,
BRAF-M% obtained by pyrosequencing was compared
with the absolute number of both alleles assessed by
picoliter-droplet digital PCR in limiting dilution conditions
and obtained similar results (Additional file 3A, B). We
thus decided to use pyrosequencing for the subsequent
quantitative analysis of BRAF V600E mutation.
As quantification of genomic DNA obtained from FFPE
samples may not be representative of BRAF mutated mes-
senger RNA (mRNA), we extracted both mRNA and gen-
omic DNA (gDNA) from 27 frozen melanoma samples.
Each sample was then analyzed with pyrosequencing as-
says designed to be specific for either cDNA or gDNA. A
high correlation (R = 0.98) of BRAF-M% between BRAF
V600E cDNA and gDNA was observed (Additional file
2B). Thus, the BRAF-M% assessed in genomic DNA from
FFPE samples by pyrosequencing may be considered rep-
resentative of the relative quantities of mutated/WT BRAF
in mRNA.
Quantification of BRAF mutation
Pyrosequencing quantification was obtained in 475 FFPE
melanoma samples from 428 patients with AJCC stage III
or IV melanoma with either V600E or WT BRAF, after
histological evaluation of the percentage of tumor cells
(flow chart in Additional file 4). No discordance concern-
ing BRAF mutational status was observed among the 46
patients with at least two distinct melanoma samples, and
the median BRAF-M% variation was 2.5 %. As expected,
according to the percentage of tumor cells in mutated
BRAF melanomas, we observed a distinct distribution of
the percentage of mutated allele (Fig. 1a). The inter-
pathologist reproducibility for the evaluation of tumor cell
content was substantial for the 80 % cut-off (κ = 0.79), and
was only moderate for the 70 % cut-off (κ = 0.49). Thus,
we decided to use the cut-off of 80 % of tumor cells. The
distribution of mutated BRAF amounts in samples with
less (n = 107) or more (n = 368) than 80 % of tumor cells
were significantly different (P < 0.05). Therefore, we thus
excluded samples with less than 80 % of melanoma cells
from further analysis.
Among the 368 remaining samples, 142 were consid-
ered BRAF mutated (38.6 %); however BRAF-M% was
highly heterogeneous (Fig. 1b), ranging from 10 % to
90 %. The majority of BRAF mutant cases (66.2 %, n = 94)
had 30 % to 60 % of BRAF-M%, and were therefore con-
sidered heterozygous. By contrast, 48 cases were consid-
ered non-heterozygous for the BRAF mutation with
BRAF-M% >60 % (n = 27) or <30 % (n = 21). Most BRAF
mutated cases with BRAF-M% from 10 % to 30 % have
been confirmed with another method and/or on an-
other sample of the same patient. Immunohistochemis-
try with VE1 was performed on whole slides in cases
with BRAF-M% <30 % when available (n = 14/21), and
none of these cases contained any tumor area with loss
of BRAF mutant expression.
In order to validate our results showing heterogeneous
distribution of BRAF-M% in mutated melanoma tumors,
we investigated the next-generation sequenced DNA
mutation data of the 104 mutated skin melanomas in
the TCGA database. The BRAF-M% from TCGA data-
base ranged from 8 to 97 %, and the distribution was in
keeping with our observation (Table 1).
Genetic causes of BRAF-M% heterogeneity
To elucidate mechanisms leading to BRAF-M% variation,
we analyzed copy number alterations of chromosome 7
and BRAF locus. FISH was performed on TMA with two
probes specific for the BRAF locus and for the chromo-
some 7 centromere. Among 125 samples, four types of
chromosome 7 alterations were observed with BRAF probe
RP11-121G9/centromere 7 (Fig. 2): no alteration (disomy),
disomy but rare cells with polysomy, polysomy, and mono-
somy, which were respectively detected in 18.4 % (n = 23),
43.2 % (n = 54), 29.6 % (n = 37) and 3.2 % (n = 4) of cases.
BRAF locus was amplified (6 to numerous BRAF copies) in
5.6 % of cases (n = 7).
FISH was also performed on 44 samples with another
probe for the BRAF locus (SureFISH 7q34 BRAF) and
similar results were obtained in all cases. To further con-
firm FISH results, we analyzed single nucleotide polymor-
phisms on chromosome 7 in 18 samples, and again all
genomic results obtained were concordant with FISH
(Table 2 and Additional file 5).
We then compared BRAF mutation allele quantity and
chromosome 7 copy number changes (Additional file 6).
Disomy of chromosome 7 - or only few cells with polys-
omy - were detected in 78 % (n = 46/59) of BRAF wild-
type samples, but in only 47 % (n = 31/66) of BRAF
mutants; however the difference didn’t reached statistical
significance (P = 0.08). Quantification of BRAF-M% was
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not validated in samples with mutations other than V600E
(n = 10/66). Correlation with FISH showed a polysomy of
chromosome 7 in 13.6 % (n = 8/59), 35.3 % (n = 12/34) and
54.5 % (n = 12/22) of wild-type, heterozygous and non-
heterozygous samples, respectively (P < 0.05) (Fig. 3).
Furthermore, none of the 22 non-heterozygous cases, ver-
sus 33.9 % (n = 20/59) of the BRAF WT group, were dip-
loid (P < 0.05). Among the 22 non-heterozygous samples,
six had low BRAF-M% (Additional file 6). Six of the 10
samples with other BRAF mutations had a polysomy of
chromosome 7.
BRAF copy number and BRAF expression
We also investigated the VE1 data for 114 samples
from TMA slides. Both VE1 and FISH data were avail-
able for 45 BRAF V600E mutated melanomas. The
VE1 staining were stronger in mutated cases showing
hyperploidy or amplification for chromosome 7 (74 %,
17/23) than in tumors with only one chromosome 7 or
with no (disomy) or minor (rare cells with polysomy)
Fig. 1 Variations in the percentage of BRAF V600E mutation in melanomas. a Scatter plot representation of the amounts of wild-type and V600E
BRAF allele distribution in relation to the percentage of tumor cells in 475 FFPE melanoma samples. b Histogram representation of the percentage
of BRAF V600E mutated allele in 368 melanomas obtained by pyrosequencing analysis. The Y axis corresponding to the number of cases is broken
between 50 and 200
Table 1 Comparison of the percentage of BRAF V600E mutation
between our series and the TCGA database
Mutant allele frequency Our study No. (%) TCGA No. (%)
<30 % 21 (14.8 %) 19 (18.3 %)a
30-60 % 94 (66.2 %) 60 (57.7 %)b
<60 % 27 (19.0 %) 25 (24.0 %)
Total 142 (100.0 %) 104 (100.0 %)
aincludes one complex mutation (P318F;V600E)
bincludes one complex mutation (K183E;V600E)
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alterations (32 %, 7/22) (P < 0.05). Interestingly, the
VE1 staining was stronger in melanomas with BRAF-
M% >60 % than in those <60 %, but this was not statis-
tically significant.
BRAF and chromosome 7 statuses in melanocytic nevi
The frequent chromosome 7 aneuploidy may be the
cause or the consequence of BRAF mutations in melano-
mas. Alternatively, it may occur in melanocyte prolifera-
tions regardless of BRAF mutations. To address this
question we analyzed 42 dermic and/or junctional melano-
cytic nevi. BRAF p.V600E mutation were detected by im-
munohistochemistry with VE1 on tissue arrays in 78.6 %
(n = 33) of nevi. In situ hybridization with probes corre-
sponding to the BRAF locus and the chromosome 7
centromere was interpretable in 27 of these 33 BRAF mu-
tant benign tumors (81.2 %), and chromosome 7 was dip-
loid in all cases (Fig. 3).
Discussion
The primary objective of this study was to assess the
percentage of BRAF mutated allele (BRAF-M%) in a
large series of human melanoma samples. For this pur-
pose, we first validated quantification by pyrosequencing
by comparing it with 2 other methods: real-time PCR
and picoliter-droplet digital PCR. We also demonstrated a
close correlation of BRAF-M% quantifications in genomic
DNA and messenger RNA. The best inter-pathologist re-
producibility of the estimation of the percentage of tumor
cells in mutated melanoma was obtained with a cut-off at
80 %. Furthermore, the mean BRAF-M% was significantly
lower for cases with <80 % of tumor cells, probably due to
the presence of the wild type non-tumor cells. We there-
fore limited the analysis to samples containing at least
80 % of tumor cells.
Using this validated quantitative method, we analyzed
BRAF-M% in a series of 368 melanoma samples and found
that it was very heterogeneous. We then investigated the
Fig. 2 Chromosome 7 alterations in human melanomas by FISH. Representative images of FISH with BRAF/chromosome 7 centromere probes in
melanomas with different chromosome 7 alterations. a no alteration (disomy) but rare cells with chromosome 7 polysomy; b chromosome 7
polysomy; c BRAF amplification; d) chromosome 7 monosomy. White bar = 10 μm
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genetic cause of this high heterogeneity by FISH and high
density SNP array, and demonstrated that chromosome 7
aneuploidy was the main mechanism of unbalanced BRAF
allelic ratio. Finally we showed that, as opposed to melano-
mas, benign melanocytic tumors with BRAF mutations did
not have any chromosome 7 instability.
Although oncogenic mutations are expected to occur
in only one of the two parental alleles, we found that
only two thirds of BRAF mutated melanomas were
heterozygous. Decreased (<30 %) and increased (>60 %)
levels of V600E mutations were detected in 14.8 % and
19 % of mutated BRAF p.V600E melanomas, respect-
ively. Unbalanced BRAF mutations have been previously
reported to be frequent in smaller series of melanoma
[14, 16, 25]; however quantitative methods were not
clearly validated, and correlation with mRNA levels was
not established. Our results were further confirmed by
analysis of the TCGA database. These results raise
Table 2 Summary of chromosome 7/BRAF genetic status by SNP array and FISH analyses in melanomas
Samples Tumor
polyploidy1










rearrangements3Copy number Allele disequilibrium
B243039 Diploid 2 AB 2 2 90 WT 7pA/7qAB
B227278 Diploid 2 AB 2 2 90 WT 7pter-7q35 AB/7q35-qter A






B228256 Poly 3 3 AAB 3 3 90 WT Non
B210964 Diploid 3 AAB 4A 3 80 WT 7pAABB/7qAAB/7qAA/7qAAB
7q complex rearrangements
B233522 Diploid 2 AB 2 4 90 WT Non
B202779 Diploid 2 AB NR 4 90 WT Non
B232220 Diploid 2 AB 3 5 90 WT Non
B236394 Diploid 2 AB NR 5,5 90 WT Non
B233492 Diploid 2 AB 3 35,5 90 V600E Non
B235230 Diploid 3 AAB 3 43 80 V600E Non
B239110 Poly 3 4 AABB NR 45 90 V600E Non
B230177 Diploid 2 AB 3 46 90 V600E Non
B226709 Poly 3 4/5 AABB/AAABBa 4B 48 90 V600E 7pter - 7q11.2 AAB/7q11.2-q35
AAABB/q35-qterAABB
B230962 Poly 3 5 AAABB 4B 50 80 V600E 7pter-7q11.22 AABB/7q11.
22-7qter AAABB
B236134 Poly 3 4/5 AABB/AAABBa 4A 51,5 90 V600E 7pter-7p21.1 AABB/7p21.1-p12.1
AAB/7p21.1-7q31.1AABB/7q3
1.1-qter AABB/AAABBa
B227502 Diploid 3 AAB NR 55,5 80 V600E 7p-7q22.3 AB/7q22.3-qter AAB
B217182 Poly 3 3 AAB 4A 61 80 V600E Non
B230859 Poly 3 5 AAABB 3 68,5 80 V600E 7pter-p21.1 AAB/7p21.1-7p11.1
AB/7qAAABB
B231121 Poly 3 3 AAB 3 74,5 90 V600E 7pter-7q13 AB/7p13-7qter AAB
B230002 Diploid 3 AAA 4A NA 90 V600K 7pter-7q21.1 AA/7q21.1-q34
AAA/7q34-qterAA
B223249 Diploid 4 AAAA NI NA 80 V600K 7pAB/7qAAA
1Tumor ploidy level was estimated by copy number analysis of SNP data
2BRAF/chromosome 7 centromere interpretation of FISH analysis: 2 – cells with two copies of chromosome 7; 3 – cells with two copies of chromosome 7 but rare
cells showing an increased number of chromosome 7; 4 – cells with chromosome 7 gains, (A) chromosome 7 in 3 or 4 copies, (B) chromosome 7 in more than 4
copies, NI – not interpretable
3Chromosome 7 genetic status presents as disequilibrium of alleles A and B (SNP analysis).
NA - not available, WT – wild-type,a - clonal aberration
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important questions concerning BRAF targeted therap-
ies. Indeed, ATP-competitive RAF inhibitors have differ-
ent effects in cells expressing wild-type or mutant BRAF
forms, with up- or down-regulation of the ERK signaling
pathway in certain in vitro conditions [26]. Furthermore,
activation of the wild-type form depends on dimerization,
while monomeric mutant forms have been shown to be ac-
tive [16]. As BRAF-M% appears to be highly heterogeneous
in melanomas, one could expect differences in response to
ATP-competitive RAF inhibitors between tumors. Data
from a recent clinical study support this hypothesis, show-
ing that the BRAF V600 mutation level was significantly
associated with a better response rate to vemurafenib dur-
ing the first 10 months of treatment [14]. In our series, two
patients with increased BRAF V600E levels (86.6 % and
86.7 %) had a prolonged disease-free survival during re-
spectively 25 and 39 months of BRAF p.V600 inhibitors
therapy. These results emphasize the appeal of mutant
BRAF quantification assessment prior to BRAF inhibitor
treatment, to correlate with clinical response rate and sur-
vival. In clinical practice, the quantification of BRAF muta-
tions deserves to be considered as a standard item in
reporting the mutational status of BRAF. Furthermore, in
vitro screening of new drugs should include cell lines with
different BRAF mutant levels, thus more closely represen-
tative of BRAF-M% in patients’ melanomas. Of note, an in
vitro study showed that 4/4 melanoma cell lines with
homozygous BRAFV600E mutations were sensible to vemur-
afenib, while 3/6 with heterozygous BRAFV600E mutations
were resistant [27].
Our initial hypothesis was that amplification of the
BRAF locus is responsible for high BRAF-M%. However,
BRAF amplification was observed in only 5.6 % of sam-
ples (n = 7), including 5 BRAF mutated cases. By con-
trast, we detected a polysomy of chromosome 7 in the
majority of cases with high BRAF-M%. A second FISH
analysis with another probe specific for the BRAF locus
and SNP analysis on chromosome 7 confirmed the qual-
ity of our FISH data.
The low BRAF-M% may be related to the presence of
non-tumor cells. Indeed, we observed a relationship be-
tween percentage of tumor cells and BRAF-M%. However
cases with low BRAF-M% were also detected when in-
cluding only samples with >80 % of tumor cells. Tumor
heterogeneity of BRAF mutated melanomas, including
some areas without BRAF mutations, have been reported
by a few groups [28, 29], and could also be responsible for
low BRAF-M%. Therefore, we performed an in situ ana-
lysis of cases with <30 % of mutant allele by immunohisto-
chemistry with the BRAF p.V600E-specific VE1 antibody
on whole slide sections. In all cases available for analysis,
no negative areas were detected. Thus the main cause of
low BRAF-M% is probably similar to high BRAF-M%. Un-
fortunately, we cannot confirm this in the present study,
because only 6 cases were analyzed by FISH. Interestingly,
BRAF mutated tumors with numerous copies of chromo-
some 7 displayed stronger VE1 staining, suggesting a
higher expression of the BRAF mutant allele.
We report herein that only 18.4 % of melanomas had no
alterations of chromosome 7. Other groups have already
shown that chromosome instability is not restricted to
chromosome 7. Indeed DNA copy number alterations
were widely studied in both primary melanomas [30, 31]
and melanoma cell lines [31–34] and frequent gains of 6p,
7, 8, 17q and 20q and losses of 9p, 10, 21q were reported.
However, these studies did not quantify the amounts of the
mutated BRAF allele. Two groups correlated chromosome
7 copy numbers with BRAF mutational status [15, 35];
however BRAF-M% was evaluated on sequence electro-
pherogram peaks. Willmore-Payne et al. detected seven
cases with chromosome 7 polysomy and two with BRAF
amplification [15]. The percentage of BRAF-mutated and
WT alleles were compared with 100 K SNP chip data for
chromosome 7 by Spittle and colleagues [25]. However,
this analysis, carried out in eight melanoma cell lines,
showed the preferential amplification of mutant BRAF as a
mechanism of an increased ratio of mutant/WT BRAF.
We detected the BRAF p.V600E mutation in 78.6 % of
dermal and/or junctional melanocytic naevi. These results
were obtained through immunohistochemistry with the
VE1 antibody, whose specificity, sensitivity and reproduci-
bility were demonstrated in melanomas [17, 22, 36]. A
similar frequency of BRAF mutations in the same types of
nevi has already been reported [37]. We then analyzed
Fig. 3 Frequency of chromosome 7 aberrations in BRAF mutant
melanoma (n = 125) and melanocytic nevi groups (n = 33).Histogram
representation of prevalence of chromosome 7 abnormalities
evaluated by FISH in 115 melanomas depending on the amounts of
V600E mutation, in 10 melanomas with BRAF exon 15 mutations
different from V600E and in 33 melanocytic nevi. WT – wild-type,
HETR – heterozygous, MUT – mutation
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chromosome 7 aneuploidy in BRAF mutated nevi with
FISH of chromosome 7. As opposed to the results obtained
in melanoma, no alterations were detected in the 27 cases
of nevi available, thus excluding a causal link between
BRAFmutations and chromosomal instability in melanocy-
tic tumors. These results are in keeping with previously
published data [38]. BRAF was previously proposed to be
the driver of copy number increase in melanoma [35]. The
present data do not support this hypothesis. However,
association of chromosome 7 aneuploidy with malig-
nancy was significant in BRAF mutated melanocytic tu-
mors (35/66 versus 0/27, P < 0.05). Our results suggest
that, among the high number of genetic alterations
present in melanomas, a frequent oncogenic pathway is
characterized by an early gain of function mutation in
BRAF and a late transforming mutation in another gene
responsible for chromosomal instability. However, this
has to be confirmed in cell models.
Conclusions
BRAF inhibitors are widely used to treat patients with
BRAF mutated melanoma, but most metastatic patients
with initial tumor response develop acquired resistance
with a median PFS of less than 7 months [10, 12]. Bio-
markers of long-term response are still missing; however a
high BRAF-M% was recently reported to be correlated with
a prolonged response. We show here that only two thirds
of BRAF V600E melanomas have a heterozygous mutation.
Thus quantitative, rather than qualitative, evaluation of
BRAF mutation deserves to be considered as a standard
item in reporting the mutational status of melanoma. Pro-
spective clinical studies are necessary to determine the
BRAF-M% prognostic impact in term of response rate or
prolonged response to BRAF inhibitors, and to confirm that
BRAF-M% could be used as a biomarker of long-term re-
sponse in clinical practice.
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Additional file 1: Oligonucleotides used for BRAF gDNA/cDNA
analysis and BRAF dPCR.
Additional file 2: Correlation analysis of BRAF V600E mutated allele
frequency. A) in 77 FFPE melanoma samples by pyrosequencing and
rtPCR. B) in gDNA and cDNA in 27 frozen melanoma samples.
Additional file 3: Picoliter-droplet digital PCR (dPCR) analysis for
BRAF V600E in melanomas. A) Representative results of dPCR analysis
for BRAF V600E on DNA obtained from 2 melanomas with different
percentage of mutated allele evaluated by pyrosequencing. On the x and
y axis are reported the fluorescence intensity of droplets positive for BRAF
V600E and BRAF wild-type, respectively. The percentage of BRAF V600E, BRAF
wild-type and empty droplets are reported in images. B) Comparison of
BRAF mutated allele frequency detected by pyrosequencing and dPCR for 7
melanoma samples.
Additional file 4: Workflow for melanoma and melanocytic nevi
samples regarding the type of molecular analysis carried out.
Additional file 5: Chromosome 7 alterations by Illumina BeadChip
HumanCore SNP array. Examples of chromosome 7 alterations in 5
BRAF V600E mutated and in one BRAF wild-type melanoma (C). In each
case, logR2 ratios for the SNP and B allele frequency are plotted on the X
axis above the chromosome ideogram. For logR2 ratios, values centered
on 0 indicate diploid copy number. Values under and above 0 indicate
losses and gains respectively. For B allele frequency, values differ from
around 0.5 indicated LOH.
Additional file 6: Summary of pyrosequencing and FISH results.
BRAF-M% and FISH results obtained for 125 melanomas analyzed by FISH
with BRAF BAC/chromosome 7 centromere probes.
Abbreviations
BAC: Bacterial artificial chromosome; BRAF-M%: Percentage of BRAF mutant
alleles; dPCR: Picoliter droplet PCR; FFPE: Formalin fixed paraffin embedded;
FISH: Fluorescence in situ hybridization; PFS: Progression-free survival;
rtPCR: real-time PCR; SNP: Single nucleotide polymorphism; TMA: Tissue
microarray; WT: Wild type.
Competing interests
VT has received honoraria from RainDance Technologies. JFE received
honoraria from Roche and Glaxo Smith Kline for counseling on patients with
melanomas on the diagnosis and/or treatment with BRAF inhibitors. PS
received honoraria for counseling on diagnosis and/or treatment of patients
with melanomas from Roche and Glaxo Smith Kline.
Authors' contributions
Conception and design: PS and JFE. Development of methodology: ZHR, LB,
CLG, VT and JFE. Study supervision: ZHR, PS and JFE. Writing of the
manuscript: ZHR, EFB, JFE. All authors participated in the acquisition, analysis
and interpretation of data (acquired and managed patients, provided
facilities, etc.). All authors read and approved the final manuscript.
Acknowledgements
The authors thank Arthur Frohlich, Maxence Tondu, Mariama Bakari, Glwadys
Faucher, Dominique Péchaud, Yolaine Pothin, Sylvie Surel and Nathalie
Terrones for technique contribution and/or data collection, Dr Alain
Beauchet for statistical analysis and Astrid Blom for article review. This work
was supported partly by grants from the Association Vaincre le Mélanome,
Ligue Contre le Cancer (Comité 92 WB2013-232), and Association pour la
Recherche et l’Enseignement en Pathologie (AREP).
Author details
1EA4340, Versailles University, Boulogne-Billancourt, France. 2Department of
Pathology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France.
3Department of Dermatology, Ambroise Paré Hospital, APHP,
Boulogne-Billancourt, France. 4Department of Hospital Pathology, College of
Medicine, The Catholic University of Korea, Seoul, Korea. 5Department of
Surgery, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France.
6INSERM UMR-S1147, University Paris Sorbonne Cite, Paris, France.
Received: 9 January 2015 Accepted: 26 June 2015
References
1. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, et
al. Analysis of ras oncogenes in malignant melanoma and precursor lesions:
correlation of point mutations with differentiation phenotype. Oncogene.
1989;11:1363–74.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations
of the BRAF gene in human cancer. Nature. 2002;417:949–54.
3. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are
different in histological types and sites of origin of cutaneous melanoma: a
meta-analysis. Br J Dermatol. 2011;164:776–84.
4. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF
mutations arise early during melanoma pathogenesis and are preserved
throughout tumor progression. Clin Cancer Res. 2003;9:6483–8.
5. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, et
al. BRAF and NRAS mutations are frequent in nodular melanoma but are
Hélias-Rodzewicz et al. BMC Cancer  (2015) 15:497 Page 9 of 10
not associated with tumor cell proliferation or patient survival. J Invest
Dermatol. 2005;125:312–7.
6. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al.
Prognostic and clinicopathologic associations of oncogenic BRAF in
metastatic melanoma. J Clin Oncol. 2011;29:1239–46.
7. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al.
Frequency and spectrum of BRAF mutations in a retrospective, single-
institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15:220–6.
8. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204
(PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor
activity in preclinical melanoma models. Cancer Res. 2010;70:5518–27.
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al.
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J
Med. 2010;363:809–19.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.
BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with
BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
11. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
N Engl J Med. 2012;366:707–14.
12. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label,
phase 3 randomised controlled trial. Lancet. 2012;380:358–65.
13. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors.
Nat Med. 2013;19:1401–9.
14. Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, et al.
BRAF(V600) mutation levels predict response to vemurafenib in metastatic
melanoma. Melanoma Res. 2014;24:415–8.
15. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. BRAF and c-kit gene
copy number in mutation-positive malignant melanoma. Hum Pathol.
2006;37:520–7.
16. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al.
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced
BRAF(V600E). Nature. 2011;480:387–90.
17. Colomba E, Hélias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N,
Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas:
comparison of four methods argues for sequential use of
immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15:94–100.
18. Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, et al.
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation
detection in clinicalformalin fixed paraffin embedded samples. Exp Mol
Pathol. 2012;92:275–80.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods.
2001;25:402–8.
20. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex
picodroplet digital PCR to detect KRAS mutations in circulating DNA from
the plasma of colorectal cancer patients. Clin Chem. 2013;59:1722–31.
21. Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F,
Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester
disease. Blood. 2014;124:3016–9.
22. Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, et
al. Prognostic value of BRAFV600 mutations inmelanoma patients after
resection of metastatic lymph nodes. Ann SurgOncol. 2012;19:4314–21.
23. Marin C, Beauchet A, Capper D, Zimmermann U, Julié C, Ilie M, et al.
Detection of BRAF p.V600E Mutations in Melanoma by
Immunohistochemistry Has a Good Interobserver Reproducibility. Arch
Pathol Lab Med. 2014;138:71–5.
24. Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR, Park GS, et al. Quantification of
BRAF V600E alleles predicts papillary thyroid cancer progression. Endocr
Relat Cancer. 2014;21:891–902.
25. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, et al.
Application of a BRAF pyrosequencing assay for mutation detection and
copy number analysis in malignant melanoma. J Mol Diagn. 2007;9:464–71.
26. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Nature. 2010;464:427–30.
27. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, et al.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to
the specific Raf inhibitor PLX4032. J Transl Med. 2010;8:39.
28. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- and
inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic
melanoma. PLoS One. 2012;7:e29336.
29. Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, et al.
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment
in BRAF(V600E) metastatic melanoma. Br J Cancer. 2013;108:924–31.
30. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al.
Distinct sets of genetic alterations in melanoma. N Engl J Med.
2005;353:2135–47.
31. Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, et al. Distinct
patterns of DNA copy number alterations associate with BRAF mutations in
melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer.
2009;48:419–28.
32. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number
analysis in melanoma using high-density single-nucleotide polymorphism
arrays. Cancer Res. 2007;67:2632–42.
33. Jönsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringnér M, et al.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene. 2007;26:4738–48.
34. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic
alterations in the melanoma genome: a high-resolution array-based comparative
genomic hybridization study. Genes Chromosomes Cancer. 2010;49:733–45.
35. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al.
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst.
2003;95:1878–90.
36. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, et al.
Immunohistochemistry is highly sensitive and specific for the detection of
V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61–5.
37. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al.
High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19–20.
38. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by
DNA copy number changes: comparative genomic hybridization as a
research and diagnostic tool. Dermatol Ther. 2006;19:40–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hélias-Rodzewicz et al. BMC Cancer  (2015) 15:497 Page 10 of 10
